Your shopping cart is currently empty

Desglymidodrine (ST 1059) is a selective α1-adrenoceptor agonist and an active metabolite of Midodrine. It is a vasoconstrictor that can be used for cardiovascular research and neurocardiogenic syncope.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $34 | In Stock | In Stock | |
| 5 mg | $77 | In Stock | In Stock | |
| 10 mg | $123 | In Stock | In Stock | |
| 25 mg | $222 | In Stock | In Stock | |
| 50 mg | $313 | In Stock | In Stock | |
| 100 mg | $467 | In Stock | In Stock | |
| 200 mg | $669 | - | In Stock |
| Description | Desglymidodrine (ST 1059) is a selective α1-adrenoceptor agonist and an active metabolite of Midodrine. It is a vasoconstrictor that can be used for cardiovascular research and neurocardiogenic syncope. |
| Targets&IC50 | α1B-adrenoceptor (rat):5.16 (pKi), α1A-adrenoceptor (rat):5.89 (pKi), α1D-adrenoceptor (rat):5.78 (pKi), α2A-adrenoceptor (human):5.83 (pKi) |
| In vitro | Desglymidodrine affects venoconstriction over a concentration range of 1-1000 μM, with a pD2 value of 4.64 (-log mol/L) in isolated canine femoral veins and 4.48 (-log mol/L) in isolated human saphenous veins. [1] Desglymidodrine binds to α1A, α1B, and α1D adrenergic receptors in rats and α2A adrenergic receptors in humans, corresponding to pKi values of 5.89, 5.16, 5.78, and 5.83, respectively. [2] |
| Synonyms | ST1059, ST 1059 |
| Molecular Weight | 197.23 |
| Formula | C10H15NO3 |
| Cas No. | 3600-87-1 |
| Smiles | OC(C1=CC(OC)=CC=C1OC)CN |
| Relative Density. | 1.145 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (202.81 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (10.14 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.